| Current Path : /proc/thread-self/root/home/ift/mails/40/ |
Linux ift1.ift-informatik.de 5.4.0-216-generic #236-Ubuntu SMP Fri Apr 11 19:53:21 UTC 2025 x86_64 |
| Current File : //proc/thread-self/root/home/ift/mails/40/1546252615.zrspam.403267_2018_12_31 |
From 4863-1954-14773-1361-christian.gabriel=shortnote.de@mail.healtheart.bid Mon Dec 31 11:36:55 2018
Return-Path: <4863-1954-14773-1361-christian.gabriel=shortnote.de@mail.healtheart.bid>
X-Original-To: cgabriel@ift-informatik.de
Delivered-To: cgabriel@ift-informatik.de
Received: by ift-informatik.de (Postfix, from userid 5555)
id 5F2453D200064; Mon, 31 Dec 2018 11:36:55 +0100 (CET)
Received: from localhost by h2486555.stratoserver.net
with SpamAssassin (version 3.4.0);
Mon, 31 Dec 2018 11:36:55 +0100
From: "Anytime Charge Power Bank" <Info@healtheart.bid>
To: <christian.gabriel@shortnote.de>
Subject: *****SPAM***** Solar Charger trial offer may end at any time
Date: Mon, 31 Dec 2018 05:36:48 -0500
Message-Id: <8u38nrhgug7glduq-2lemi8cw8h4ulaso-39b5@healtheart.bid>
X-Spam-Checker-Version: SpamAssassin 3.4.0 (2014-02-07) on
h2486555.stratoserver.net
X-Spam-Flag: YES
X-Spam-Level: ******
X-Spam-Status: Yes, score=6.0 required=5.0 tests=BAYES_00,DKIM_SIGNED,
DKIM_VALID,DKIM_VALID_AU,HTML_FONT_LOW_CONTRAST,HTML_MESSAGE,MIME_HTML_MOSTLY,
MPART_ALT_DIFF,RAZOR2_CF_RANGE_51_100,RAZOR2_CF_RANGE_E8_51_100,RAZOR2_CHECK,
RCVD_IN_PSBL,RDNS_NONE,T_REMOTE_IMAGE autolearn=no autolearn_force=no
version=3.4.0
MIME-Version: 1.0
Content-Type: multipart/mixed; boundary="----------=_5C29F147.62090478"
This is a multi-part message in MIME format.
------------=_5C29F147.62090478
Content-Type: text/plain; charset=iso-8859-1
Content-Disposition: inline
Content-Transfer-Encoding: 8bit
Spam detection software, running on the system "h2486555.stratoserver.net",
has identified this incoming email as possible spam. The original
message has been attached to this so you can view it or label
similar future email. If you have any questions, see
@@CONTACT_ADDRESS@@ for details.
Content preview: Content-Transfer-Encoding: 8bit Untitled Document TEST THE
"ANYTIME CHARGE" NOW WHILE SUPPLIES LAST! [...]
Content analysis details: (6.0 points, 5.0 required)
pts rule name description
---- ---------------------- --------------------------------------------------
2.7 RCVD_IN_PSBL RBL: Received via a relay in PSBL
[185.148.243.177 listed in psbl.surriel.com]
0.0 HTML_MESSAGE BODY: HTML included in message
0.0 HTML_FONT_LOW_CONTRAST BODY: HTML font color similar or identical to
background
-1.9 BAYES_00 BODY: Bayes spam probability is 0 to 1%
[score: 0.0000]
0.4 MIME_HTML_MOSTLY BODY: Multipart message mostly text/html MIME
0.8 MPART_ALT_DIFF BODY: HTML and text parts are different
0.1 DKIM_SIGNED Message has a DKIM or DK signature, not necessarily valid
-0.1 DKIM_VALID Message has at least one valid DKIM or DK signature
-0.1 DKIM_VALID_AU Message has a valid DKIM or DK signature from author's
domain
0.9 RAZOR2_CHECK Listed in Razor2 (http://razor.sf.net/)
0.5 RAZOR2_CF_RANGE_51_100 Razor2 gives confidence level above 50%
[cf: 100]
1.9 RAZOR2_CF_RANGE_E8_51_100 Razor2 gives engine 8 confidence level
above 50%
[cf: 100]
0.8 RDNS_NONE Delivered to internal network by a host with no rDNS
0.0 T_REMOTE_IMAGE Message contains an external image
The original message was not completely plain text, and may be unsafe to
open with some email clients; in particular, it may contain a virus,
or confirm that your address can receive spam. If you wish to view
it, it may be safer to save it to a file and open it with an editor.
------------=_5C29F147.62090478
Content-Type: message/rfc822; x-spam-type=original
Content-Description: original message before SpamAssassin
Content-Disposition: attachment
Content-Transfer-Encoding: 8bit
Received: from akron.healtheart.bid (unknown [185.148.243.177])
by ift-informatik.de (Postfix) with ESMTP id 002533D200033
for <christian.gabriel@shortnote.de>; Mon, 31 Dec 2018 11:36:52 +0100 (CET)
DKIM-Signature: v=1; a=rsa-sha1; c=relaxed/relaxed; s=k1; d=healtheart.bid;
h=Mime-Version:Content-Type:Date:From:Reply-To:Subject:To:Message-ID; i=Info@healtheart.bid;
bh=CaHWggJoWiFEN9WeL5X+xyLDOCE=;
b=GbFiNaBHZacgcmKFVuSanjTpkfEuwqNRo0KslXezsODV982oPO7yYj5ydXhSv7z7NbCsLMw3bs0o
AxuysWNjP8Y0UV5i4jaDRuZNmpEdfbM7VcCC5B1PisbOjDktuXXIajNKRg+0M/bkf80OX7x2UjnF
twXbZc8Cj6g4b+z7arE=
DomainKey-Signature: a=rsa-sha1; c=nofws; q=dns; s=k1; d=healtheart.bid;
b=jTT/bL5MA3Vjn3We5l4vI3ycxyeBZsF2ptCDhlgOCXCk00Rm+LVT2qJJ04z8CqyLckIBYbI5mRfI
A3HPa2EG5a0hLhm30c6vvj4ZYuTBv40iuCSfAs22Hrb2kx4JljBF+onfGkf1J018mvTCkiU2AxTW
v1Il9ycSrJ+QO8kG97g=;
Mime-Version: 1.0
Content-Type: multipart/alternative; boundary="0d39393b51610dbef312f34ef347cf79"
Date: Mon, 31 Dec 2018 05:36:48 -0500
From: "Anytime Charge Power Bank" <Info@healtheart.bid>
Reply-To: "Anytime Charge Power Bank" <Support@healtheart.bid>
Subject: Solar Charger trial offer may end at any time
To: <christian.gabriel@shortnote.de>
Message-ID: <8u38nrhgug7glduq-2lemi8cw8h4ulaso-39b5@healtheart.bid>
--0d39393b51610dbef312f34ef347cf79
Content-Type: text/plain;
Content-Transfer-Encoding: 8bit
--0d39393b51610dbef312f34ef347cf79
Content-Type: text/html;
Content-Transfer-Encoding: 8bit
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<title>Untitled Document</title>
</head>
<body><a href="http://healtheart.bid/clk.14773-4863-0-1954-1361-2276-4aabdc57-0300"><img border="0" src="http://healtheart.bid/clk.14773-4863-14-1954-1361-2276-825507ab-0300" /> </a>
<table align="center" style="font-size:16px;font-family:Cambria;text-align:justify" width="700">
<tbody>
<tr>
<td align="center" style="font-size:24px;background-color:#171717;color:#EA0000;text-shadow:8px 8px 8px #FF5151">
<p>TEST THE "ANYTIME CHARGE" NOW WHILE SUPPLIES LAST!</p>
</td>
</tr>
<tr>
<td><a href="http://healtheart.bid/clk.14773-4863-2-1954-1361-2276-b6333c91-0300" target="_blank"><img src="http://healtheart.bid/5c7ad84f009e1f751c.JPG" width="700" /></a></td>
</tr>
<tr>
<td>
<p>I promise, the Anytime Charge is going to be your new favorite "every day" power source. It's lightweight and compact yet holds enough power to recharge your phone, tablet and any other device that can be charged via a USB cable. It's also perfect for camping and hiking so you will always have a power source!</p>
<p>We've done the field testing. We've taken it on long hikes, camping, hunting trips, we've used it as an every day power source to re-charge cells and tablets and this charger passed all our hardcore stress tests all while being user friendly enough for every day use!</p>
<p>But, if you want to test this out for free you've got to jump on this offer fast and get one right now because we have limited stock! <a href="http://healtheart.bid/clk.14773-4863-2-1954-1361-2276-b6333c91-0300" target="_blank"><b>So claim this offer right now to get your Anytime Charge!</b></a></p>
</td>
</tr>
<tr>
<td align="center" style="font-size:12px;"><br />
<br />
<br />
<br />
<br />
<br />
Remove from our Email List <a href="http://healtheart.bid/clk.14773-4863-12-1954-1361-2276-92ecf3a7-0300"> press this link </a><br />
4262 New York Avenue Sherman Oaks, CA 91403</td>
</tr>
<tr>
<td align="left" height="30"> </td>
</tr>
</tbody>
</table>
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<span style="color:#FFFFFF;background-color:#FFFFFF; font-family:constantia,lucida bright,dejavu serif,georgia,serif; font-size:5px">Vitamin D might be one of those ways to prevent type 2 diabetes. nThis summer, researchers reported that there seemed to be a connection between a lack of vitamin D, gum disease, and type 2 diabetes. They weren’t sure yet what the connection is. It may be that a lack of vitamin D causes gum disease and one or the other increases the odds of developing diabetes. Another study published in October suggested that an appetite suppressant drug could help lower the risk of diabetes. The drug is lorcaserin, known by its brand name Belviq. In a study involving 12,000 participants, it showed promise in reducing blood glucose levels as well as the overall risk of kidney complications related to diabetes in people struggling with their weight. Treating diabetes and its symptoms also made news in 2018. The drug metformin is used by an estimated 120 million people with diabetes worldwide to control blood sugar and insulin levels. Early this year, however, it was reported that the common medication is also the one people with diabetes are most likely to stop taking. The reason is the disruption metformin sometimes causes in a person’s digestive system. For many people with diabetes, the daily ritual of pricking their finger to apply a drop of blood on a test strip can be an obstacle to diabetes management.</span>
<p align="center"><a href="http://healtheart.bid/clk.14773-4863-20-1954-1361-2276-4cd6edf0-0300"><img src="http://healtheart.bid/249d8ccdc40c9a4f5f.jpg" /></a></p>
</body>
</html>
--0d39393b51610dbef312f34ef347cf79--
------------=_5C29F147.62090478--